{
    "relation": [
        [
            "Arms",
            "Experimental: Doravirine 25 mg doravirine 25 mg + TRUVADA\u00ae Participants in this arm will receive doravirine 25 mg in Part 1 and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part 2. These participants also receive placebo that matches efavirenz.",
            "Experimental: Doravirine 50 mg Doravirine 50 mg + TRUVADA\u00ae Participants in this arm will receive doravirine 50 mg in Part 1 and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part 2. These participants also receive placebo that matches efavirenz.",
            "Experimental: Doravirine 100 mg Doravirine 100 mg + TRUVADA\u00ae Participants in this arm will receive doravirine 100 mg in Part 1 and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part 2. These participants also receive placebo that matches efavirenz.",
            "Experimental: Doravirine 200 mg Doravirine 200 mg + TRUVADA\u00ae Participants in this arm will receive doravirine 200 mg in Part 1 and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part 2. These participants also receive placebo that matches efavirenz.",
            "Active Comparator: Efavirenz Efavirenz + TRUVADA\u00ae Participants in this arm will receive efavirenz in Part 1 and in Part 2. These participants also receive placebo that matches doravirine."
        ],
        [
            "Assigned Interventions",
            "Drug: Doravirine Part 1: doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) tablet or placebo matching doravirine orally every morning with or without food for at least 24 weeks When the doravirine selected dose is determined after all participants reach Week 24, participants on other doses of doravirine will be switched to the selected dose for the remainder of the 96-week study. Part 2: Selected dose of doravirine (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet or placebo matching doravirine orally every morning with or without food for 96 weeks Drug: TRUVADA\u00ae Open-label TRUVADA\u00ae (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks",
            "Drug: Doravirine Part 1: doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) tablet or placebo matching doravirine orally every morning with or without food for at least 24 weeks When the doravirine selected dose is determined after all participants reach Week 24, participants on other doses of doravirine will be switched to the selected dose for the remainder of the 96-week study. Part 2: Selected dose of doravirine (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet or placebo matching doravirine orally every morning with or without food for 96 weeks Drug: TRUVADA\u00ae Open-label TRUVADA\u00ae (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks",
            "Drug: Doravirine Part 1: doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) tablet or placebo matching doravirine orally every morning with or without food for at least 24 weeks When the doravirine selected dose is determined after all participants reach Week 24, participants on other doses of doravirine will be switched to the selected dose for the remainder of the 96-week study. Part 2: Selected dose of doravirine (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet or placebo matching doravirine orally every morning with or without food for 96 weeks Drug: TRUVADA\u00ae Open-label TRUVADA\u00ae (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks",
            "Drug: Doravirine Part 1: doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) tablet or placebo matching doravirine orally every morning with or without food for at least 24 weeks When the doravirine selected dose is determined after all participants reach Week 24, participants on other doses of doravirine will be switched to the selected dose for the remainder of the 96-week study. Part 2: Selected dose of doravirine (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet or placebo matching doravirine orally every morning with or without food for 96 weeks Drug: TRUVADA\u00ae Open-label TRUVADA\u00ae (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks",
            "Drug: Efavirenz Efavirenz 600 mg tablet or placebo matching efavirenz orally at bedtime taken without food on an empty stomach for 96 weeks Drug: TRUVADA\u00ae Open-label TRUVADA\u00ae (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks"
        ]
    ],
    "pageTitle": "A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA\u00ae Versus Efavirenz Plus TRUVADA\u00ae in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/show/NCT01632345?order=203",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042985647.51/warc/CC-MAIN-20150728002305-00051-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 870822759,
    "recordOffset": 870813187,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{480=The hypothesis tested in this study is that MK-1439 at the final dose selected is superior to efavirenz, each given in combination with TRUVADA\u00ae, as measured by the proportion of participants with CNS events by Week 8. If superiority is established at Week 8, the same hypothesis will be tested for Week 24., 1015=Part 2 - Selected Dose. Part 2 will be initiated after the doravirine dose has been selected as indicated above for Part 1. Approximately 120 additional participants will be randomized in 1:1 ratio to the selected dose of doravirine or efavirenz, each in combination with TRUVADA\u00ae for 96 weeks of blinded treatment. Part 2 will evaluate the safety of the selected dose compared with efavirenz, particularly with regard to central nervous system adverse events (CNS events).}",
    "textBeforeTable": "December 2014 (Final data collection date for primary outcome measure) Primary Completion Date: April 2016 Estimated Study Completion Date: October 2012 Study Start Date: 320 Estimated Enrollment: Change from Baseline in CD4 Cell Counts [\u00a0Time\u00a0Frame:\u00a0Baseline and 96 Weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Percentage of Participants with HIV RNA <200 copies/mL [\u00a0Time\u00a0Frame:\u00a096 Weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Number of Participants with any Clinical or Laboratory Adverse Event [\u00a0Time\u00a0Frame:\u00a096 Weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0] Percentage of Participants with HIV RNA <40 copies/mL [\u00a0Time\u00a0Frame:\u00a096 Weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Change from Baseline in CD4 Cell Counts [\u00a0Time\u00a0Frame:\u00a048 Weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Percentage of Participants with HIV RNA <200 copies/mL Analyzed for Part 1 and Part 2 combined Analyzed for Part 1 and Part 2 combined Analyzed for Part 1 and Part 2 combined Analyzed for Part 1 and Part 2 combined Analyzed for Part 1 and Part 2 combined Analyzed for Part 1 and Part 2 combined",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years and older Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: HIV-1 positive No previous use of antiretroviral therapy (ART) No signs of active pulmonary disease within 45 days before the start of study treatment Clinically stable with no signs or symptoms of acute infection No change in clinical status or chronic medications for at least 2 weeks before the start of study treatment Participants of reproductive potential agree to remain abstinent in line with their preferred and usual lifestyle or use (or have their partner use) 2 acceptable methods of birth control throughout the study and for 12 weeks post study. Participants not of reproductive potential, not sexually active, whose current partner(s) is not of reproductive potential, or whose sexual activity is exclusively homosexual are eligible without requiring the use of contraception. Exclusion Criteria: Males planning",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}